Hepatitis B: Modern End Points of Treatment and the Specter of Viral Resistance
Authors:
- 30 September 2011
- journal article
- review article
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 40 (3) , 495-505
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- 376 SYSTEMATIC REVIEW AND META-ANALYSIS: PREVALENCE OF SIGNIFICANT HISTOLOGIC DISEASE IN CHRONIC HEPATITIS B INFECTION, HIGH HBVDNA, AND PERSISTENTLY NORMAL SERUM ALT (PNALT)Journal of Hepatology, 2011
- Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e antigen-Negative Chronic Hepatitis BDigestive Diseases and Sciences, 2011
- Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus InfectionDigestive Diseases and Sciences, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †Hepatology, 2009
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatology International, 2008
- Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg‐negative chronic hepatitis B virus infectionJournal of Viral Hepatitis, 2008
- New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNAJournal of Hepatology, 2005
- Sampling Variability of Liver Fibrosis in Chronic Hepatitis CHepatology, 2003
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999